01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories reported solid financial results for the third quarter and first nine months of 2024, showcasing robust top-line growth driven by its Medical Devices and Established Pharmaceutical Products segments.
Despite a notable decline in COVID-19 testing sales, the company achieved an overall 4.9%a increase in net sales in Q3 and 3.7% for the nine-month period, with organic growth (excluding foreign exchange) at 7.4% and 6.7%, respectively. The Medical Devices segment, in particular, demonstrated strong double-digit growth in key areas like Diabetes Care, Electrophysiology, and Structural Heart, highlighting successful product launches and strategic partnerships. Profitability also saw improvement, with gross profit margins increasing year-over-year due to higher pricing and efficiency initiatives, partially offsetting foreign exchange headwinds.
While research and development expenses saw a modest increase, selling, general, and administrative costs were managed effectively. The company also continues to prioritize shareholder returns through dividend payments and share repurchases, demonstrating confidence in its financial stability and future outlook.
However, investors should remain aware of ongoing legal proceedings, particularly the significant jury verdict in an infant formula lawsuit, although Abbott plans to appeal and does not currently believe a material loss is probable. Additionally, ongoing tax examinations by the IRS present a potential area of future scrutiny.
02—Key points
Key Highlights
- Total net sales increased by 4.9% to $10.635 billion in Q3 2024 and by 3.7% to $30.976 billion for the first nine months of 2024, with organic growth (excluding foreign exchange) of 7.4% and 6.7% respectively.
- Medical Devices segment demonstrated strong performance with an 11.7% increase in Q3 and 12.0% increase for the nine months (excluding foreign exchange), driven by significant growth in Diabetes Care, Electrophysiology, and Structural Heart products.
- Gross profit margin improved to 51.4% in Q3 2024 and 51.0% for the nine months, up from 49.7% and 50.1% in the prior year periods, respectively, reflecting pricing benefits and efficiency initiatives.
- Diluted Earnings Per Common Share (EPS) rose to $0.94 in Q3 2024 from $0.82 in Q3 2023, and to $2.38 for the nine months from $2.35 in the prior year.
- The company repurchased approximately 7 million shares for $750 million in Q3 2024 and announced a new $7 billion share repurchase program, underscoring commitment to shareholder returns.
- COVID-19 testing-related sales continued to decline, impacting the Diagnostic Products segment, with sales down 24.0% (excluding FX) for Rapid Diagnostics in the first nine months.
- Abbott faces significant legal proceedings, including a $495 million jury verdict in an infant formula NEC lawsuit, which the company plans to appeal. Reserves have not been recorded as a material loss is not deemed probable.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Abbott Laboratories kept $0.15.
- Revenue$10.63B100.0%
- Cost of revenue−$4.70B44.2%
- Gross profit$5.94B55.8%
- Operating costs−$4.08B38.3%
- Operating income$1.86B17.5%
- Interest, other & tax−$213.0M2.0%
- Net income$1.65B15.5%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $10.63B$10.14B | +4.9% |
| Cost of Revenue | $4.70B$4.61B | +2.0% |
| Gross Profit | $5.94B$5.54B | +7.2% |
| R&D Expenses | $713.00M$672.00M | +6.1% |
| SG&A Expenses | $2.90B$2.72B | +6.3% |
| Operating Expenses | $8.78B$8.50B | +3.3% |
| Operating Income | $1.86B$1.65B | +12.9% |
| Net Income | $1.65B$1.44B | +14.6% |
| EPS (Basic) | $0.94$0.82 | +14.6% |
| EPS (Diluted) | $0.94$0.82 | +14.6% |
| Shares Outstanding (Basic) | 1.74B1.74B | 0.0% |
| Shares Outstanding (Diluted) | 1.75B1.75B | 0.0% |
05—Questions
Frequently Asked Questions
How did Abbott Laboratories' revenue perform in the third quarter and first nine months of 2024?
Abbott Laboratories reported a 4.9% increase in net sales to $10.635 billion for the third quarter of 2024 and a 3.7% increase to $30.976 billion for the first nine months of 2024 compared to the same periods in 2023. Excluding the impact of foreign exchange, sales grew by 7.4% in Q3 and 6.7% for the nine-month period. This growth was primarily driven by the Medical Devices and Established Pharmaceutical Products segments, partially offset by a decrease in COVID-19 testing sales.
What were the key growth drivers within the Medical Devices segment?
The Medical Devices segment showed robust performance, with sales increasing by 11.7% in the third quarter and 12.0% for the first nine months of 2024 (excluding foreign exchange). Key growth drivers included double-digit growth in Diabetes Care (driven by continuous glucose monitoring systems), Electrophysiology, Structural Heart, and Heart Failure products. The company also highlighted strategic partnerships and FDA clearances for new devices, such as the FreeStyle Libre 2 Plus sensor integration and over-the-counter CGM systems.
What is the company's stance on the recent jury verdict in the infant formula lawsuit, and what is the financial impact?
Abbott Laboratories denies the allegations in lawsuits claiming its infant formula products cause necrotizing enterocolitis (NEC). While a jury in Missouri awarded a plaintiff $495 million in July 2024, Abbott plans to appeal the verdict. The company stated that it does not believe a material loss is probable from these lawsuits and has therefore not recorded any reserves. However, the resolution of these cases could be material to the company's financial position, cash flows, or results of operations.
How is Abbott managing its cost structure and profitability?
Abbott has demonstrated an improvement in its gross profit margin, reaching 51.4% in the third quarter and 51.0% for the first nine months of 2024, up from 49.7% and 50.1% respectively in the prior year. This improvement is attributed to favorable pricing in various businesses and ongoing gross margin improvement initiatives. While R&D expenses increased, the company managed its selling, general, and administrative expenses effectively, partially benefiting from favorable foreign exchange rates.
06—Continue